A detailed history of Private Capital Group, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Private Capital Group, LLC holds 285 shares of NKTR stock, worth $256. This represents 0.0% of its overall portfolio holdings.

Number of Shares
285
Previous 251 13.55%
Holding current value
$256
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 28, 2022

BUY
$3.17 - $6.17 $107 - $209
34 Added 13.55%
285 $1,000
Q1 2022

Apr 21, 2022

BUY
$4.16 - $13.72 $628 - $2,071
151 Added 151.0%
251 $1,000
Q4 2021

Jan 24, 2022

BUY
$10.83 - $18.41 $357 - $607
33 Added 49.25%
100 $1,000
Q3 2020

Nov 12, 2020

BUY
$16.59 - $24.79 $1,111 - $1,660
67 New
67 $1,000
Q1 2020

May 07, 2020

SELL
$14.47 - $27.96 $824 - $1,593
-57 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$15.87 - $23.12 $999 - $1,456
-63 Reduced 52.5%
57 $1,000
Q3 2019

Nov 13, 2019

BUY
$16.91 - $36.27 $1,707 - $3,663
101 Added 531.58%
120 $2,000
Q2 2019

Aug 15, 2019

BUY
$31.0 - $36.3 $589 - $689
19 New
19 $1,000
Q4 2018

Jan 28, 2019

SELL
$30.43 - $56.65 $608 - $1,133
-20 Closed
0 $0
Q3 2018

Oct 31, 2018

BUY
$46.46 - $68.49 $46 - $68
1 Added 5.26%
20 $1,000
Q2 2018

Aug 09, 2018

SELL
$46.25 - $104.45 $18,176 - $41,048
-393 Reduced 95.39%
19 $0
Q1 2018

May 16, 2018

BUY
$57.4 - $108.44 $574 - $1,084
10 Added 2.49%
412 $44,000
Q4 2017

May 18, 2018

BUY
$23.02 - $60.5 $8,862 - $23,292
385 Added 2264.71%
402 $24,000
Q4 2017

Mar 07, 2018

BUY
$23.02 - $60.5 $391 - $1,028
17
17 $1,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $169M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Private Capital Group, LLC Portfolio

Follow Private Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Capital Group, LLC with notifications on news.